Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
QuantumPharm, Inc. ( (HK:2228) ) just unveiled an announcement.
XtalPi Holdings Limited announced that it expects its 2024 revenue to reach HK$250,000,000, positioning it to potentially transition from a Pre-Commercial to a Commercial Company under Hong Kong Stock Exchange rules. The announcement highlights the company’s growth driven by its drug discovery and intelligent automation services, though the results are based on unaudited accounts and may differ from final audited results.
More about QuantumPharm, Inc.
XtalPi Holdings Limited, formerly known as QuantumPharm Inc., operates in the pharmaceutical industry, providing drug discovery and intelligent automation solutions. The company is focused on leveraging business developments and market opportunities to advance its offerings and reach significant revenue milestones.
YTD Price Performance: 10.54%
Average Trading Volume: 119,281,280
Technical Sentiment Consensus Rating: Strong Sell
For a thorough assessment of 2228 stock, go to TipRanks’ Stock Analysis page.